This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quilliam, B. J. Articles by Leibson, C. Search for Related Content PubMed PubMed Citation Articles by Quilliam, B. J. Articles by Leibson, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN Medline Plus Health Information Nursing Homes Stroke Related Collections Secondary prevention Anticoagulants Antiplatelets Epidemiology

(Stroke. 2001;32:1385.)
© 2001 American Heart Association, Inc.

Original Contributions

Clinical Correlates and Drug Treatment of Residents With Stroke in Long-Term Care

Brian J. Quilliam, PhD Kate L. Lapane, PhD

From Brown University Department of Community Health (B.J.Q., K.L.L.) and Brown University Center for Gerontology and Health Care Research (K.L.L.), Providence, RI.

Correspondence to Kate L. Lapane, PhD, Brown University, Box G-B222, Providence, RI 02912. E-mail Kate_Lapane{at}brown.edu

Background and Purpose—Stroke incidence increases with age, and stroke survivors often require nursing home placement. Characteristics of these residents and factors associated with the secondary drug prevention of stroke in nursing homes have yet to be explored.

Methods—We used a population-based data set of all nursing home residents in 5 states (1992 to 1995). We identified 53 829 (20.4%) with a diagnosis of stroke on the Minimum Data Set assessment. We considered aspirin, dipyridamole, ticlopidine, or warfarin alone or in combination as secondary drug prevention. We used logistic regression modeling to identify independent predictors of drug treatment.

Results—Sixty-seven percent of stroke survivors were not receiving drug therapy for stroke prevention. Among those treated, most received aspirin alone (16%) or warfarin alone (10%). Independent predictors of drug treatment included comorbid conditions (eg, hypertension, atrial fibrillation, depression, Alzheimer’s disease, dementia, gastrointestinal bleeding, and peptic ulcer disease). Those over the age of 85 years were less likely to be treated than those 65 to 74 years of age (odds ratio [OR], 0.86; 95% confidence interval [CI], 0.82 to 0.91); black residents were less likely to be treated than whites (OR, 0.80; 95% CI, 0.75 to 0.85); and those with severe cognitive (OR, 0.63; 95% CI, 0.60 to 0.67) or physical impairment (OR, 0.69; 95% CI, 0.64 to 0.75) were also less likely to receive drug treatment.

Conclusions—Stroke is highly prevalent in long-term care. Despite the increased risk of subsequent stroke in the elderly, many are not being treated. The choice to treat or not to treat may be influenced by age, comorbidity, race/ethnicity, and cognitive or physical functioning.

Editorial Comment

Cynthia Leibson, PhD, Guest Editor

Department of Health Sciences Research, Mayo Clinic Foundation, Rochester, Minnesota

This article has been cited by other articles:

				B. Ovbiagele, O. Drogan, W. J. Koroshetz, P. Fayad, and J. L. Saver Outpatient Practice Patterns After Stroke Hospitalization Among Neurologists Stroke, June 1, 2008; 39(6): 1850 - 1854. [Abstract] [Full Text] [PDF]

				N. A. Nickman, J. Biskupiak, F. Creekmore, H. Shah, and D. I . Brixner Antiplatelet medication management in patients hospitalized with ischemic stroke Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2250 - 2256. [Abstract] [Full Text] [PDF]

				G. E. Kikano and M. T. Brown Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician Mayo Clin. Proc., May 1, 2007; 82(5): 583 - 593. [Abstract] [Full Text] [PDF]

				B. Ovbiagele, N. K. Hills, J. L. Saver, S. C. Johnston, and for the CASPR Investigators Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA Neurology, February 14, 2006; 66(3): 313 - 318. [Abstract] [Full Text] [PDF]

				L. Leeds, J. Meara, and P. Hobson The impact of discharge to a care home on longer term stroke outcomes Clinical Rehabilitation, August 1, 2004; 18(8): 924 - 928. [Abstract] [PDF]

				J. B. Christian, K. L. Lapane, and R. S. Toppa Racial Disparities in Receipt of Secondary Stroke Prevention Agents Among US Nursing Home Residents Stroke, November 1, 2003; 34(11): 2693 - 2697. [Abstract] [Full Text] [PDF]

				F Landi, M Cesari, G Onder, V Zamboni, F Lattanzio, A Russo, C Barillaro, and R Bernabei Antithrombotic drugs in secondary stroke prevention among a community dwelling older population J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1100 - 1104. [Abstract] [Full Text] [PDF]

				B. J. Quilliam, K. L. Lapane, C. B. Eaton, and V. Mor Effect of Antiplatelet and Anticoagulant Agents on Risk of Hospitalization for Bleeding Among a Population of Elderly Nursing Home Stroke Survivors Stroke, October 1, 2001; 32(10): 2299 - 2304. [Abstract] [Full Text] [PDF]